Ignite Creation Date:
2024-05-05 @ 11:33 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00079872
Status:
COMPLETED
Last Update Posted:
2007-11-06
First Post:
2004-03-17
Brief Title:
Pemetrexed Plus a Comparator Versus a Combination of 2 Comparators in First-Line Treatment of Colorectal Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Randomized Phase 2 Trial of ALIMTA Plus a Comparator Versus Leucovorin Modulated Fluorouracil Plus a Comparator in First Line Treatment of Locally Advanced or Metastatic Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2007-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
In this study patients will receive either pemetrexed plus irinotecan or 5-fluorouracil 5-FU leucovorin and irinotecan
The purposes of this study are to determine
How pemetrexed plus irinotecan compares with 5-FU leucovorin and irinotecan in terms of efficacy
The safety of pemetrexed plus irinotecan and any side effects that might be associated with it as compared with 5-FU leucovorin and irinotecan
Whether pemetrexed can help patients with colorectal cancer
The purposes of this study are to determine
How pemetrexed plus irinotecan compares with 5-FU leucovorin and irinotecan in terms of efficacy
The safety of pemetrexed plus irinotecan and any side effects that might be associated with it as compared with 5-FU leucovorin and irinotecan
Whether pemetrexed can help patients with colorectal cancer
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| H3E-MC-JMAZ | None | None | None |